Biosortia Pharmaceuticals, Inc.
Biosortia Pharmaceuticals is a company focused on drug discovery from unculturable aquatic microorganisms, leveraging unique microbiome and natural product chemistry technologies. It collaborates with academic institutions and industry partners to develop novel therapeutics, particularly in cancer, infectious diseases, and metabolic disorders. The company is engaged in innovative research, strategic partnerships, and has received recognition for its contributions to biopharmaceutical discovery.
Industries
Nr. of Employees
small (1-50)
Products
Library of consortia‑derived natural products
A curated collection of compounds and partially refined mixtures derived from aquatic microbial consortia intended for use in early‑stage drug discovery screening.
Library of consortia‑derived natural products
A curated collection of compounds and partially refined mixtures derived from aquatic microbial consortia intended for use in early‑stage drug discovery screening.
Services
Contract or collaborative arrangements that provide academic and industry researchers with access to libraries of natural products and supporting screening data for drug discovery programs.
Contract or collaborative arrangements that provide academic and industry researchers with access to libraries of natural products and supporting screening data for drug discovery programs.
Expertise Areas
- Natural products drug discovery
- Aquatic microbiome sampling and harvesting
- Microalgal consortia assessment and scouting
- Preclinical oncology and infectious disease discovery
Key Technologies
- In‑situ aquatic microbiome harvesting
- Continuous natural product discovery platform
- Microalgal consortia scouting/sampling technology
- Natural product extraction and fractionation
News & Updates
Biosortia announced the addition of Dr. Haiyin He to its research leadership team to enhance its natural products drug discovery efforts.
The company launched new oncology research projects investigating microalgal compounds for potential cancer therapeutics.
Biosortia performs assessments of microalgal consortia across multiple U.S. states to identify new sources for drug discovery.
The company partners with NOAA to discover and extract beneficial compounds from algae.
The company relocates to San Diego to join J&J’s incubator and plans to expand in Ohio.
A study on the prognostic value of microbiomes in cancer recurrence.
Biosortia announced the addition of Dr. Haiyin He to its research leadership team to enhance its natural products drug discovery efforts.
The company launched new oncology research projects investigating microalgal compounds for potential cancer therapeutics.
Biosortia performs assessments of microalgal consortia across multiple U.S. states to identify new sources for drug discovery.
The company partners with NOAA to discover and extract beneficial compounds from algae.
The company relocates to San Diego to join J&J’s incubator and plans to expand in Ohio.
A study on the prognostic value of microbiomes in cancer recurrence.